Showing results (121-130 of 208) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|June 9, 2017
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialMichael A Davies, Philippe Saiag, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2022
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain MetastasesJames S Wilmott, Hussein Tawbi, Johnathan A Engh, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
Future Oncology (London, England)|February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
Pageof 21